CLDN6 defines a liver-metastatic CMS4 subgroup in colorectal cancer via CLDN6–SRC–FOXO1 signaling and epigenetic reprogramming

Abstract Background Liver-metastatic colorectal cancer (CRC) of the consensus molecular subtype 4 (CMS4) is aggressive and exhibits poor response to cetuximab, particularly in the presence of FBXW7 mutations. Moreover, the CMS4 subtype of metastatic CRC lacks a stable and robust genomic signature for accurately predicting the development of liver metastasis. This study aimed to identify clinically actionable surface drivers of CMS4 progression and to establish a targeted therapeutic strategy. Methods Multicenter clinical cohorts, bulk and single-cell transcriptomic datasets, and multi-omics analyses were integrated to screen candidate surface markers associated with metastatic CRC. Functional studies using CRC cell models examined effects on adhesion, migration, tumor growth, and liver metastasis. RNA-seq, ATAC-seq, ChIP-seq, protein-interaction analyses, and site-directed mutagenesis were combined to delineate downstream signaling and epigenetic mechanisms. A small-molecule screen was further performed to identify compounds disrupting the relevant protein interaction, followed by validation in patient-derived organoid (PDO) and xenograft (PDX) models. Results CLDN6 was enriched in liver-metastatic CMS4 CRC and was associated with FBXW7-mutant tumors and poor clinical outcome. Functionally, CLDN6-positive tumor cells displayed reduced adhesion-related programs, enhanced motility, and increased tumor growth and liver-metastatic colonization. Mechanistically, phosphorylation of CLDN6 at Y196/Y200 promoted binding to the SRC SH2 domain and sustained SRC activation, leading to FOXO1 phosphorylation and cytoplasmic sequestration. Nuclear FOXO1 directly activated adhesion-related genes and induced KDM6B, which reduced H3K27me3-mediated repression at these loci, thereby establishing a transcriptional–epigenetic mechanism linking CLDN6 signaling to loss of tumor-cell adhesion. Disruption of CLDN6 phosphorylation or CLDN6–SRC interaction reversed these effects. AP20187 suppressed CRC PDO viability and enhanced the antitumor activity of oxaliplatin plus cetuximab in the FBXW7-mutant PDX model. Conclusions CLDN6 defines a biologically and therapeutically distinct liver-metastatic CMS4 CRC subgroup. The CLDN6–SRC–FOXO1–KDM6B axis links a surface-associated signaling event to transcriptional and epigenetic repression of adhesion programs, providing a mechanistic basis for targeting CLDN6-associated signaling in FBXW7-mutant CRC.

Authors

Institutions

Publication Details

Journal
Journal of Experimental & Clinical Cancer Research
Published
2026-11-15
DOI
https://doi.org/10.1186/s13046-026-03878-1
Primary Topic
Colorectal Cancer Treatments and Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

CLDN6 defines a liver-metastatic CMS4 subgroup in colorectal cancer via CLDN6–SRC–FOXO1 signaling and epigenetic reprogramming

Yongjie Xie, Chunnuan Wu, Qingwu Du, Feng Liu et al.
Journal of Experimental & Clinical Cancer Research
Colorectal Cancer Treatments and Studies
article

CLDN6 defines a liver-metastatic CMS4 subgroup in colorectal cancer via CLDN6–SRC–FOXO1 signaling and epigenetic reprogramming

Yongjie Xie, Chunnuan Wu, Qingwu Du, Feng Liu, Rui Li, Bo Ni, Yaoyao Zhou, Yamei Han, Chao Liu, Wenxia Zhao, Ziyun Liu, Jie Zhang, Shihui Cao
article en

Abstract

Abstract Background Liver-metastatic colorectal cancer (CRC) of the consensus molecular subtype 4 (CMS4) is aggressive and exhibits poor response to cetuximab, particularly in the presence of FBXW7 mutations. Moreover, the CMS4 subtype of metastatic CRC lacks a stable and robust genomic signature for accurately predicting the development of liver metastasis. This study aimed to identify clinically actionable surface drivers of CMS4 progression and to establish a targeted therapeutic strategy. Methods Multicenter clinical cohorts, bulk and single-cell transcriptomic datasets, and multi-omics analyses were integrated to screen candidate surface markers associated with metastatic CRC. Functional studies using CRC cell models examined effects on adhesion, migration, tumor growth, and liver metastasis. RNA-seq, ATAC-seq, ChIP-seq, protein-interaction analyses, and site-directed mutagenesis were combined to delineate downstream signaling and epigenetic mechanisms. A small-molecule screen was further performed to identify compounds disrupting the relevant protein interaction, followed by validation in patient-derived organoid (PDO) and xenograft (PDX) models. Results CLDN6 was enriched in liver-metastatic CMS4 CRC and was associated with FBXW7-mutant tumors and poor clinical outcome. Functionally, CLDN6-positive tumor cells displayed reduced adhesion-related programs, enhanced motility, and increased tumor growth and liver-metastatic colonization. Mechanistically, phosphorylation of CLDN6 at Y196/Y200 promoted binding to the SRC SH2 domain and sustained SRC activation, leading to FOXO1 phosphorylation and cytoplasmic sequestration. Nuclear FOXO1 directly activated adhesion-related genes and induced KDM6B, which reduced H3K27me3-mediated repression at these loci, thereby establishing a transcriptional–epigenetic mechanism linking CLDN6 signaling to loss of tumor-cell adhesion. Disruption of CLDN6 phosphorylation or CLDN6–SRC interaction reversed these effects. AP20187 suppressed CRC PDO viability and enhanced the antitumor activity of oxaliplatin plus cetuximab in the FBXW7-mutant PDX model. Conclusions CLDN6 defines a biologically and therapeutically distinct liver-metastatic CMS4 CRC subgroup. The CLDN6–SRC–FOXO1–KDM6B axis links a surface-associated signaling event to transcriptional and epigenetic repression of adhesion programs, providing a mechanistic basis for targeting CLDN6-associated signaling in FBXW7-mutant CRC.

Journal of Experimental & Clinical Cancer Research
Tianjin Medical University Cancer Institute and Hospital (CN), Zhengzhou University (CN), Henan Cancer Hospital (CN), Tianjin Medical University (CN)
Colorectal Cancer Treatments and Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon